UBS Initiates Esperion Therapeutics With Buy - Esperion Therapeutics (NASDAQ:ESPR)

MEMORIAL DAY FLASH SALE: 50% OFF BENZINGA PRO

As we honor our freedom, take a stand today. Secure the financial freedom that both you and your family deserve. Get exclusive market moving news for just 50% off. Claim your 50% discount here.

Analysts at UBS initiated coverage on Esperion Therapeutics, Inc. (NASDAQ: ESPR) with a Buy rating.The target price for Esperion Therapeutics is set to $140.Esperion Therapeutics shares have gained 525.68% over the past 52 weeks, while the S&P 500 index has surged 9.36% in the same period.Esperion Therapeutics' shares rose 4.21% to $96.50 in pre-market trading.

MEMORIAL DAY FLASH SALE: 50% OFF BENZINGA PRO

As we honor our freedom, take a stand today. Secure the financial freedom that both you and your family deserve. Get exclusive market moving news for just 50% off. Claim your 50% discount here.

ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!